For Healthcare Professionals Outside the US
AE, adverse event; CDK, cyclin-dependent kinase; EMA, European Medicines Agency.
All trademarks referenced are the property of their respective owners.
References: 1. KISQALI [Summary of Product Characteristics]. Novartis Pharma AG; 2017. 2. Burris HA, Chan A, Campone M, et al. First-line ribociclib + letrozole in patients with HR+, HER2– advanced breast cancer presenting with visceral metastases or bone-only disease: a subgroup analysis of the MONALEESA-2 trial. Poster presented at: San Antonio Breast Cancer Symposium; December 6-10, 2016; San Antonio, TX. Poster P4-22-16. 3. Data on file. Novartis Pharma AG. 4. Ibrance [Summary of Product Characteristics]. Sandwich, United Kingdom: Pfizer Limited; 2016.